跳至主要内容
临床试验/JPRN-jRCT1080225086
JPRN-jRCT1080225086已完成Unknown

An Observational Study for Investigating the Frequency of FGFR2 Gene Fusion in Unresectable Advanced or Metastatic Cholangiocarcinoma

Eisai Co., Ltd.0 个研究点目标入组 550 人开始时间: 2020年2月25日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
入组人数
550

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 1.Provide written informed consent
  • 2.Male or female subjects age >= 20 years at the time of informed consent
  • 3.Subjects with a histologically or cytologically diagnosis of intrahepatic or perihilar cholangiocarcinoma
  • 4.Subjects with surgically unresectable or advanced/metastatic disease
  • 5.Subjects with Performance Status (PS) score of 0 1 established by Eastern Cooperative Oncology Group (ECOG)
  • 6.Subjects who are expected to survive for 3 months or longer after Informed consent.

排除标准

  • 1. History of active malignancy (except for primary tumor or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, carcinoma in-situ of the cervix, or early stage colorectal cancer) within the past 24 months prior to informed consent
  • 2. Patients with prior therapy targeting FGFR2
  • 3. Any subjects who are judged by the principal investigator or sub-investigators to be inappropriate as subjects in this study

研究者

相似试验